City Therapeutics director Robert Nelsen reports $3.06 million common share acquisition
CTY•City Therapeutics director and 10% owner Robert Nelsen reported an indirect purchase of 170,000 common shares at $18 each, totaling $3.06 million. His reported indirect holdings totaled 13,692,507 shares through ARCH Venture Fund XII.
1. Reported share purchase
Robert Nelsen reported an indirect purchase of 170,000 City Therapeutics common shares at $18 per share. His reported indirect holdings totaled 13,692,507 common shares through ARCH Venture Fund XII.
2. Conversions and options
Conversions of Series Seed, Series A and Series B convertible preferred stock added 10,804,215 common shares. Nelsen also received options to buy 22,649 common shares at an $18 exercise price.
